Canada - English - Health Canada

pfizer canada ulc - moroctocog alfa - powder for solution - 1000unit - moroctocog alfa 1000unit - hemostatics

Canada - English - Health Canada

pfizer canada ulc - moroctocog alfa - powder for solution - 2000unit - moroctocog alfa 2000unit - hemostatics

Canada - English - Health Canada

pfizer canada ulc - moroctocog alfa - powder for solution - 3000unit - moroctocog alfa 3000unit - hemostatics

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - octocog alfa -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - moroctocog alfa 3000 [iu];   - injection with diluent - 3000 iu - active: moroctocog alfa 3000 [iu]   excipient: calcium chloride dihydrate histidine polysorbate 80 sodium chloride sucrose sodium chloride water for injection - xyntha is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - lonoctocog alfa -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - lonoctocog alfa -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - lonoctocog alfa -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - lonoctocog alfa -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - lonoctocog alfa -